Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 6—June 2020
Research

Characterization of Sporadic Creutzfeldt-Jakob Disease and History of Neurosurgery to Identify Potential Iatrogenic Cases

Tsuyoshi Hamaguchi, Kenji Sakai, Atsushi Kobayashi, Tetsuyuki Kitamoto, Ryusuke Ae, Yosikazu Nakamura, Nobuo Sanjo, Kimihito Arai, Mizuho Koide, Fumiaki Katada, Masafumi Harada, Hiroyuki Murai, Shigeo Murayama, Tadashi Tsukamoto, Hidehiro Mizusawa, and Masahito YamadaComments to Author 
Author affiliations: Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan (T. Hamaguchi, K. Sakai, M. Yamada); Hokkaido University, Sapporo, Japan (A. Kobayashi); Tohoku University Graduate School of Medicine, Sendai, Japan (T. Kitamoto); Jichi Medical University, Shimotsuke, Japan (R. Ae, Y. Nakamura); Tokyo Medical and Dental University, Tokyo, Japan (N. Sanjo); National Hospital Organization Chiba-East Hospital, Chiba, Japan (K. Arai, M. Koide); Kameda Medical Center, Chiba (F. Katada); The University of Tokushima, Tokushima, Japan (M. Harada); International University of Health and Welfare, Narita, Japan (H. Murai); Tokyo Metropolitan Institute of Gerontology, Tokyo (S. Murayama); National Center of Neurology and Psychiatry, Kodaira, Japan (T. Tsukamoto, H. Mizusawa)

Main Article

Table 1

Comparison of the clinical features of patients with Creutzfeldt-Jakob disease with and without history of neurosurgery*

Patient characteristics Neurosurgery No neurosurgery p value
Total no. patients
 27
 1,128
Sex, no. (%)
F 17 (63.0) 647 (57.4) 0.353
M
 10 (37)
 481 (42.6)
Age at onset, y + SD (range) 71.0 + 8.8 (49–88) 68.7 + 9.6 (30–91) 0.217
Disease duration, mo + SD (range)† 6.1 + 7.8 (1–28) 6.7 + 12.0 (0–171) 0.823
Duration from neurosurgery to onset of CJD, y + SD (range)
 15.0 + 9.1 (1–35)
Polymorphism at codon 129 of prion protein gene, no. (%)
MM 25 (92.6) 1,101 (97.6) 0.138
MV 2 (7.4) 22 (1.9)
VV
 0
 5 (0.4)
Negative rate of PSWCs on EEG, no. (%) 5 (18.5) 64/1,121 (5.7) 0.019
14-3-3 protein in CSF, no. tested/no. positive (%) 20/22 (90.9) 675/803 (84.1) 0.300
Tau protein in CSF, cutoff 1,200 pg/mL, no. tested/no. positive (%) 13/14 (92.9) 503/567 (88.7) 0.523

*CJD, Creutzfeldt-Jakob disease; CSF, cerebrospinal fluid; EEG, electroencephalogram; PSWCs, periodic sharp-wave complexes
†Disease duration of CJD: duration between the onset of CJD and the appearance of the akinetic mutism or death in the patients who died without akinetic mutism

Main Article

Page created: May 18, 2020
Page updated: May 18, 2020
Page reviewed: May 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external